{
    "65cfad2d1930410b13000014":
    {
        "question": "Concizumab is used for which diseases?",
        "llm_evidence": "Concizumab is a monoclonal antibody that functions as an inhibitor of tissue factor, primarily under investigation for its potential use in hemophilia. It is designed to facilitate hemostasis by blocking the initiation of the coagulation cascade, which is particularly beneficial for individuals with hemophilia A or B who face challenges with bleeding episodes. Additionally, concizumab has shown promise in treating hereditary angioedema (HAE), a genetic condition characterized by recurrent episodes of severe swelling. Clinical trials have demonstrated its efficacy in managing these conditions, making concizumab a potentially valuable therapeutic option for patients with hemophilia and HAE."
    },
    "65f7736fc4010b4d78000024":
    {
        "question": "What type of extracolonic tumors does the PMS2 germline mutation cause?",
        "llm_evidence": "PMS2 germline mutations are associated with Lynch syndrome (also known as hereditary non-polyposis colorectal cancer, or HNPCC), which primarily increases the risk for various extracolonic tumors. Key insights include:\n\n1. **Endometrial Cancer**: There is a significantly elevated risk of endometrial cancer in individuals with PMS2 mutations, often manifesting before the age of 50.\n\n2. **Ovarian Cancer**: Although the risk is lower compared to other Lynch syndrome mutations (like MLH1 and MSH2), PMS2 mutations still confer an increased risk for ovarian cancer.\n\n3. **Urinary Tract Cancers**: There is a notable association with urinary tract cancers, particularly urothelial carcinoma.\n\n4. **Gastric Cancer**: Individuals with PMS2 mutations may also have an increased risk of gastric cancer, although this is less prominent compared to other Lynch-related mutations.\n\n5. **Small Bowel Cancer**: Research indicates a potential increased risk for small bowel cancer, a lesser-known but possible outcome of PMS2 mutations.\n\nIn summary, PMS2 germline mutations are linked to an increased risk of various extracolonic tumors, particularly endometrial, ovarian, urinary tract, gastric, and small bowel cancers."
    },
    "65f7080fc4010b4d78000019":
    {
        "question": "Do stroke patients have a lower risk of Obstructive Sleep Apnea?",
        "llm_evidence": "Patients who have experienced a stroke may face a higher, rather than lower, risk of developing Obstructive Sleep Apnea (OSA). Research indicates that stroke can lead to various physiological changes, including disruptions in the central nervous system that may impact sleep patterns and respiratory control. Additionally, common factors associated with stroke, such as obesity, hypertension, and cardiovascular issues, are also known risk factors for OSA. Studies have shown that a significant percentage of stroke patients are found to have OSA, suggesting a correlation rather than a protective effect. Overall, the evidence points to an increased risk of OSA in stroke patients, emphasizing the need for thorough screening and management of sleep apnea in this population."
    },
    "65f859b2c4010b4d78000050":
    {
        "question": "Should all babies diagnosed with spina bifida be operated within the first week of life?",
        "llm_evidence": "Spina bifida is a congenital condition characterized by the incomplete development of the spinal cord and surrounding structures. Surgical intervention aims to minimize neurological damage and improve outcomes. Recent evidence suggests that early intervention, ideally within the first week of life, can significantly reduce the risk of complications such as infection and further neurological impairment. Studies indicate that early surgery is associated with improved mobility and quality of life for affected infants. However, the decision should also consider the severity of the condition, potential surgical risks, and individual patient factors. Multidisciplinary evaluation and parental involvement in treatment decisions are crucial. Consequently, while early surgery is often beneficial, it is essential to tailor the approach to each individual case."
    },
    "6446884b57b1c7a31500006f":
    {
        "question": "What is Oculopharyngeal Muscular Dystrophy (OPMD)?",
        "llm_evidence": "Oculopharyngeal Muscular Dystrophy (OPMD) is a rare genetic disorder characterized by progressive muscle weakness, particularly affecting the ocular (eye) and pharyngeal (throat) muscles. It is typically caused by mutations in the PABPN1 gene, leading to the accumulation of abnormal proteins in muscle cells. OPMD often manifests in adulthood, with symptoms including ptosis (drooping of the eyelids), dysphagia (difficulty swallowing), and weakness in the facial and limb muscles. The condition may also result in respiratory issues as it progresses. Diagnosis typically involves clinical evaluation, genetic testing, and muscle biopsies. Treatment options are limited and mainly focus on managing symptoms, such as surgical intervention for ptosis and dietary modifications for swallowing difficulties. Overall, OPMD highlights the importance of genetic factors in muscle degenerative diseases and underscores the need for ongoing research into effective therapies."
    },
    "65d144731930410b13000040":
    {
        "question": "What is the mechanisms of action of Dersimelagon?",
        "llm_evidence": "Dersimelagon, also known as MT-350, is an investigational drug that primarily functions as a dual agonist of the melanocortin-1 receptor (MC1R) and melanocortin-4 receptor (MC4R). The mechanisms of action of Dersimelagon involve the stimulation of these receptors, which play crucial roles in regulating energy homeostasis, thermogenesis, and appetite.\n\n1. **MC1R Agonism**: Activation of MC1R enhances the production of melanin, which is important for skin pigmentation and may influence metabolic processes. This receptor's stimulation is associated with increased lipolysis and energy expenditure.\n\n2. **MC4R Agonism**: MC4R is pivotal in the regulation of appetite and body weight. When activated by Dersimelagon, it helps curb excessive food intake and promotes weight loss by increasing energy expenditure. This action can potentially benefit conditions such as obesity and metabolic syndrome.\n\nTogether, the agonistic actions on MC1R and MC4R create a synergistic effect that targets both metabolic regulation and weight management, which are vital for treating metabolic disorders. This dual mechanism is essential in exploring Dersimelagon's therapeutic potential for obesity-related diseases."
    },
    "65f7728fc4010b4d78000021":
    {
        "question": "What proportion of risk is attributable to obesity in colorectal cancer women development?",
        "llm_evidence": "Obesity is recognized as a significant risk factor for the development of colorectal cancer (CRC), particularly among women. Epidemiological studies indicate that approximately 20-30% of colorectal cancer cases in women can be attributed to obesity. The mechanisms underlying this relationship include hormonal changes, inflammation, and insulin resistance associated with excess body weight, which can promote tumorigenesis. Additionally, women with a body mass index (BMI) of 30 or higher have been shown to have a substantially higher risk of developing colorectal cancer compared to those with a normal weight. Overall, the evidence supports that obesity plays a critical role in increasing the risk of colorectal cancer in women, highlighting the importance of weight management as a preventive measure."
    },
    "65f490fac4010b4d78000010":
    {
        "question": "Has MDMA(ecstasy) been successfully used to treat PTSD disorder?",
        "llm_evidence": "MDMA (3,4-methylenedioxymethamphetamine), commonly known as ecstasy, has shown promise as a treatment for Post-Traumatic Stress Disorder (PTSD) in recent clinical studies. Research conducted by organizations such as the Multidisciplinary Association for Psychedelic Studies (MAPS) has demonstrated that MDMA-assisted psychotherapy can significantly reduce PTSD symptoms. \n\nKey insights include:\n\n1. **Clinical Trials**: Phase 2 and Phase 3 trials have indicated that patients receiving MDMA as part of their therapy experienced substantial improvements, with many achieving remission from PTSD symptoms.\n\n2. **Mechanism of Action**: MDMA is thought to facilitate therapeutic breakthroughs by enhancing emotional engagement, reducing fear responses, and promoting feelings of safety and connection during therapy sessions, which can help patients confront traumatic memories.\n\n3. **Long-term Effects**: Follow-up studies suggest that the positive effects of MDMA-assisted therapy can be sustained over time, with participants reporting improvements lasting for months after treatment.\n\n4. **FDA Designation**: In 2021, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for MDMA-assisted psychotherapy for PTSD, indicating its potential as a significant treatment option.\n\n5. **Safety Profile**: Clinical studies have generally reported a favorable safety profile when MDMA is administered in controlled settings, monitored by trained professionals.\n\nOverall, evidence from clinical studies and ongoing research supports the potential of MDMA as a transformative treatment for PTSD, leading to significant symptom relief and improved quality of life for affected individuals."
    },
    "65f843cbc4010b4d78000042":
    {
        "question": "What is a spillover event?",
        "llm_evidence": "A spillover event refers to the process by which diseases or pathogens jump from one species to another, often from animals to humans. This phenomenon typically occurs when humans come into close contact with wildlife or through environmental changes that disrupt ecosystems. Key insights include:\n\n1. **Zoonotic Transmission**: Many spillover events involve zoonoses, where diseases like SARS, Ebola, and COVID-19 originate from animal hosts and infect humans.\n\n2. **Environmental Factors**: Deforestation, urbanization, and climate change can increase the likelihood of spillover by altering habitats and bringing wildlife into closer proximity with people.\n\n3. **Public Health Implications**: Understanding spillover events is crucial for preventing pandemics, as early detection and monitoring of potential zoonotic diseases can inform public health responses.\n\n4. **Research and Surveillance**: Ongoing research and surveillance of wildlife can provide insights into emerging infectious diseases and enhance preparedness for future spillover events.\n\nIn essence, spillover events highlight the intricate connections between human health, animal health, and environmental integrity."
    },
    "64467f8657b1c7a31500006d":
    {
        "question": "How can Emery-Dreifuss Muscular Dystrophy (EDMD) be inherited?",
        "llm_evidence": "Emery-Dreifuss Muscular Dystrophy (EDMD) can be inherited in three primary ways: X-linked, autosomal dominant, and autosomal recessive. \n\n1. **X-linked inheritance**: The most common form of EDMD, which is associated with mutations in the EMD gene located on the X chromosome. This primarily affects males, while females may be carriers and present milder symptoms.\n\n2. **Autosomal dominant inheritance**: In this form, the disorder can be caused by mutations in the genes such as EMD or LMNA, and only one copy of the mutated gene from an affected parent is sufficient to pass the condition to offspring. Both males and females are equally likely to be affected.\n\n3. **Autosomal recessive inheritance**: In rare cases, EDMD can result from mutations in genes like LMNA when both copies of the gene (one from each parent) are mutated. This form is more common in siblings from consanguineous unions.\n\nOverall, the inheritance pattern significantly influences the clinical presentation and severity of EDMD among affected individuals."
    },
    "65d12b451930410b13000031":
    {
        "question": "Can valproate be used during pregnancy?",
        "llm_evidence": "Valproate, also known as valproic acid, is an anticonvulsant medication that is generally advised against during pregnancy due to its associated risks. Key insights include:\n\n1. **Teratogenicity**: Studies have shown that valproate is highly teratogenic, significantly increasing the risk of congenital malformations such as neural tube defects, spinal bifida, and other serious abnormalities in the developing fetus when taken during the first trimester.\n\n2. **Developmental Risks**: Beyond physical defects, exposure to valproate in utero is linked to developmental issues, including an increased risk of autism spectrum disorders and cognitive impairment in children.\n\n3. **Guidelines and Recommendations**: Health authorities, such as the FDA and the European Medicines Agency (EMA), strongly discourage the use of valproate in pregnant women or those planning to become pregnant. Alternative treatments are recommended whenever possible.\n\n4. **Risk Mitigation**: For women of childbearing age who are prescribed valproate, healthcare providers often recommend effective contraception and discuss the risks associated with its use during pregnancy.\n\nIn conclusion, while some cases may require careful consideration of the benefits versus risks, the consensus among medical guidelines is that the use of valproate during pregnancy poses significant risks to fetal health and development."
    },
    "65f7725ec4010b4d78000020":
    {
        "question": "Which dietary compounds are associated with colorectal cancer incidence?",
        "llm_evidence": "Several dietary compounds have been associated with colorectal cancer incidence, including:\n\n1. **Red and Processed Meat**: High consumption of red meat (such as beef, pork, and lamb) and processed meats (like bacon, sausages, and deli meats) is linked to increased colorectal cancer risk. The heme iron found in red meat and the presence of nitrites and nitrates in processed meats are thought to play a role in this association.\n\n2. **Dietary Fiber**: A diet rich in dietary fiber, particularly from whole grains, fruits, and vegetables, is associated with a reduced risk of colorectal cancer. Fiber helps to promote healthy bowel movements and may have protective effects against cancer by aiding in the elimination of potential carcinogens.\n\n3. **Fruits and Vegetables**: High intake of fruits and vegetables may lower colorectal cancer risk, likely due to their high content of vitamins, antioxidants, and phytochemicals that exhibit anti-inflammatory and anti-carcinogenic properties.\n\n4. **Calcium and Vitamin D**: Some studies suggest that higher calcium and vitamin D intake may be protective against colorectal cancer, potentially influencing cellular processes that control cell growth and differentiation.\n\n5. **Alcohol Consumption**: Excessive alcohol intake is associated with an increased risk of colorectal cancer. The mechanism may involve the formation of acetaldehyde, a potential carcinogen generated during alcohol metabolism.\n\n6. **Sugars and High Glycemic Index Foods**: Diets high in sugars and refined carbs may be linked to an increased risk of colorectal cancer, possibly due to their role in promoting obesity and insulin resistance, both of which are risk factors for cancer.\n\nCollectively, these insights indicate that dietary choices play a significant role in the incidence of colorectal cancer, highlighting the importance of a balanced diet rich in fiber, fruits, and vegetables, while limiting red and processed meats and alcohol."
    },
    "65f494d7c4010b4d78000013":
    {
        "question": "What is the relationship between  Electroporation (EP) and DNA vaccines?",
        "llm_evidence": "Electroporation (EP) is a physical method that enhances the delivery of DNA vaccines into cells by applying an electrical field, which temporarily disrupts the cell membrane. This process increases the permeability of the cell membrane, allowing plasmid DNA to enter more efficiently. Key insights about the relationship between EP and DNA vaccines include:\n\n1. **Increased Transfection Efficiency**: EP significantly improves the uptake of DNA plasmids, leading to higher expression levels of encoded antigens and, consequently, stronger immune responses.\n\n2. **Robust Immune Response**: Studies have shown that electroporated DNA vaccines elicit both humoral (antibody-mediated) and cellular (T-cell mediated) immune responses more effectively than traditional vaccination methods.\n\n3. **Versatile Application**: EP can be adapted for various vaccine delivery modalities, such as intramuscular or intradermal routes, making it a flexible tool in vaccine development.\n\n4. **Clinical Success**: Several clinical trials have demonstrated the safety and immunogenicity of electroporated DNA vaccines against infectious diseases and cancers, indicating successful translation from laboratory to real-world application.\n\nOverall, the integration of electroporation in DNA vaccine technology has significantly enhanced vaccine efficacy, making it a critical tool in modern vaccinology."
    },
    "65f84d20c4010b4d7800004a":
    {
        "question": "Is measles immunisation the best public health approach to reduce incidence of measles worldwide?",
        "llm_evidence": "Measles immunisation is widely regarded as the most effective public health approach to reduce the incidence of measles worldwide. Key insights supporting this conclusion include:\n\n1. **High Efficacy of Vaccination**: The measles vaccine is approximately 97% effective after two doses. This high efficacy significantly reduces the number of cases and the spread of the virus within communities.\n\n2. **Herd Immunity**: Achieving a vaccination coverage of at least 95% in a population is crucial for establishing herd immunity, which protects those who are unable to be vaccinated (e.g., infants, immunocompromised individuals) by reducing overall circulation of the virus.\n\n3. **Decline in Mortality and Morbidity**: The introduction of the measles vaccine has led to a dramatic decline in mortality and morbidity rates associated with measles. According to the World Health Organization (WHO), global measles deaths dropped by 73% from 2000 to 2018 due to improved vaccination coverage.\n\n4. **Cost-Effectiveness**: Immunisation programs are cost-effective public health interventions. The return on investment from measles vaccines in terms of healthcare savings and societal benefits is substantial.\n\n5. **Global Health Initiatives**: International health organizations, including WHO and UNICEF, emphasize the importance of vaccination as part of routine childhood immunization programs, aiming to eliminate measles as a public health threat.\n\nOverall, comprehensive immunisation strategies, including outreach and education to increase vaccine uptake, are essential in achieving significant reductions in measles incidence globally."
    },
    "64179034690f196b5100002b":
    {
        "question": "What type of DMD can golodirsen be used for?",
        "llm_evidence": "Golodirsen is a targeted therapy designed for patients with Duchenne Muscular Dystrophy (DMD) who have specific mutations in the dystrophin gene, particularly those that are amenable to exon 53 skipping. It functions by promoting the production of a shorter but functional form of the dystrophin protein, which is crucial for muscle function. Clinical trials have demonstrated that golodirsen can improve dystrophin protein levels in muscle tissue, supporting its use as a treatment option for DMD caused by these mutations."
    },
    "65d137871930410b1300003e":
    {
        "question": "What are active ingredients of Trikafta?",
        "llm_evidence": "Trikafta is a prescription medication primarily used to treat cystic fibrosis in patients aged 12 years and older who have specific mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The active ingredients in Trikafta are:\n\n1. **Elexacaftor**: A CFTR corrector that helps the defective protein respond better to the normal cellular processes, enhancing the amount of protein at the cell surface.\n\n2. **Tezacaftor**: Another CFTR corrector that works in conjunction with elexacaftor to improve the folding and trafficking of the CFTR protein to the cell surface.\n\n3. **Ivacaftor**: A CFTR potentiator that helps to increase the function of the mutant CFTR protein at the cell surface, facilitating chloride ion transport across the epithelial cell membranes.\n\nThese active ingredients work synergistically to improve lung function and reduce respiratory symptoms in individuals with cystic fibrosis."
    },
    "65f77397c4010b4d78000025":
    {
        "question": "What proportion of alteration in NTRK genes are attributable to colorectal cancer?",
        "llm_evidence": "NTRK gene alterations are relatively rare in colorectal cancer, accounting for a small percentage of cases. While NTRK fusions, primarily identified in other cancers such as mammary tumors and certain sarcomas, have been well-documented, their occurrence in colorectal cancer is significantly lower, with studies showing that these alterations are present in approximately 1-4% of colorectal cancer cases. This low prevalence indicates that while NTRK gene alterations can occur, colorectal cancer is not a primary driver of these mutations compared to other cancer types. Overall, the burden of NTRK alterations attributable to colorectal cancer is minimal, highlighting the need for further research to understand the role and impact of these mutations in this particular cancer type."
    },
    "65f1d234c4010b4d78000005":
    {
        "question": "Please list the Janus Kinase inhibitors used to treat Inflammatory Bowel Disease(IBD)",
        "llm_evidence": "Janus Kinase (JAK) inhibitors are a class of medications that target specific pathways involved in the inflammatory response and have been shown to be effective in treating Inflammatory Bowel Disease (IBD). The notable JAK inhibitors used for IBD include:\n\n1. **Tofacitinib (Xeljanz)**: Originally approved for rheumatoid arthritis, Tofacitinib is also indicated for ulcerative colitis. It works by inhibiting JAK1 and JAK3, thereby reducing the inflammatory process.\n\n2. **Risankizumab (Skyrizi)**: This JAK inhibitor has shown effectiveness in the treatment of ulcerative colitis and is currently undergoing various clinical trials for Crohn's disease. \n\n3. **Filgotinib (Jyseleca)**: It has been evaluated for the treatment of ulcerative colitis and works primarily on JAK1 inhibition.\n\n4. **Upadacitinib (Rinvoq)**: Approved for rheumatoid arthritis, Upadacitinib is in the process of being studied for its efficacy in treating moderate to severe ulcerative colitis.\n\nRecent studies suggest that these JAK inhibitors can provide significant improvements in clinical outcomes for patients with IBD, emphasizing their role in the management of this chronic condition."
    },
    "65f83281c4010b4d78000040":
    {
        "question": "Are only babies and young children at risk of severe malaria in endemic areas?",
        "llm_evidence": "Severe malaria primarily affects vulnerable populations, including babies and young children, who have limited immunity against Plasmodium parasites in endemic areas. However, it is not exclusively these age groups that are at risk. Adults, particularly those who are pregnant, elderly, or have compromised immune systems, can also experience severe malaria. In endemic regions, repeated exposure to malaria leads to a degree of immunity over time, but this immunity can wane, especially in adults who have not been exposed for extended periods. Moreover, factors such as nutritional status, co-infections, and access to healthcare can further increase the risk of severe outcomes in individuals of any age. Therefore, while babies and young children are particularly susceptible, other demographic groups can also be significantly impacted by severe malaria."
    },
    "64414bdb57b1c7a315000058":
    {
        "question": "What types of glucosteroids are used for the management of Duchenne muscular dystrophy?",
        "llm_evidence": "Duchenne muscular dystrophy (DMD) management commonly involves the use of glucocorticoids, particularly prednisone and deflazacort. Prednisone is widely used and has been found to improve muscle strength and function while delaying the progression of the disease. Deflazacort, a newer glucocorticoid, has a similar efficacy but may be associated with fewer side effects, such as less weight gain and better preservation of bone health. Both medications work by reducing inflammation and modulating immune responses, ultimately prolonging ambulation and improving quality of life for patients with DMD. Ongoing research is also exploring the potential benefits of other glucocorticoids and corticosteroid regimens to optimize treatment outcomes."
    },
    "65cfd4b21930410b13000020":
    {
        "question": "Cilta-cel was developed for treatment of which disease?",
        "llm_evidence": "Cilta-cel, or ciltacabtagene autoleucel, is a CAR T-cell therapy specifically developed for the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. Clinical trials have demonstrated its efficacy in patients with relapsed or refractory multiple myeloma, particularly after they have undergone previous treatments. The therapy works by genetically modifying a patient's T-cells to target and attack cancerous plasma cells, leading to significant improvements in response rates and progression-free survival in affected individuals."
    },
    "65f772d3c4010b4d78000022":
    {
        "question": "Which oncogene somatic mutations are associated to in situ carcinoma evolution from colonic polyp adenomas?",
        "llm_evidence": "In the evolution of colonic polyp adenomas to in situ carcinoma, several key oncogene somatic mutations play a critical role. The most prominent mutations are found in the following oncogenes:\n\n1. **KRAS**: Mutations in the KRAS gene are among the earliest events in the adenoma-to-carcinoma sequence. Approximately 30-40% of colorectal cancers exhibit KRAS mutations, which are often detected in adenomatous polyps, particularly tubular adenomas. This mutation leads to uncontrolled cell growth and proliferation.\n\n2. **BRAF**: BRAF mutations, especially the BRAF V600E variant, are associated with a subset of colorectal cancers, particularly those arising from serrated lesions. This mutation is linked to the serrated pathway of colorectal cancer development and can lead to the progression of sessile serrated adenomas to carcinoma.\n\n3. **PIK3CA**: Somatic mutations in the PIK3CA gene, which encodes a subunit of the phosphatidylinositol 3-kinase, are also recurrently observed in colorectal cancers and can contribute to tumorigenesis through the activation of the PI3K/Akt signaling pathway.\n\n4. **TP53**: While TP53 is primarily known as a tumor suppressor gene, mutations in TP53 are also common later in the progression from adenoma to carcinoma. These mutations usually occur after KRAS and BRAF mutations and are associated with the transition to invasive cancer.\n\nOverall, the progression from colonic polyp adenomas to in situ carcinoma often involves a series of genetic alterations, primarily in oncogenes such as KRAS and BRAF, alongside mutations in tumor suppressor genes like TP53. The presence of these mutations not only facilitates the understanding of tumor progression but also enhances the potential for targeted therapies in colorectal cancer management."
    },
    "65f1eb84c4010b4d78000008":
    {
        "question": "What is prurigo nodularis?",
        "llm_evidence": "Prurigo nodularis is a chronic skin condition characterized by the presence of intensely itchy nodules (bumps) on the skin. These lesions typically arise in response to repetitive scratching or rubbing, often due to underlying conditions like atopic dermatitis or chronic kidney disease. The nodules can be quite painful, leading to a cycle of itching and further skin damage. Histologically, the condition is marked by thickened skin with an inflammatory infiltrate. Treatment options include topical corticosteroids, antihistamines for itch relief, and, in some cases, systemic therapies such as immunosuppressants or phototherapy. Effective management often requires addressing the underlying triggers to reduce itch and prevent lesion formation."
    },
    "65f8447fc4010b4d78000043":
    {
        "question": "What is the main cause of spillover events?",
        "llm_evidence": "Spillover events primarily occur due to the transmission of pathogens from wildlife to humans, often facilitated by ecological changes and human activities. Key insights into the main causes include:\n\n1. **Habitat Alteration**: Deforestation, urbanization, and agriculture encroach on natural habitats, increasing human-wildlife interactions which heightens the risk of zoonotic diseases spilling over to people.\n\n2. **Globalization and Trade**: The movement of goods and people across borders can introduce novel pathogens to new environments. The wildlife trade, in particular, is a significant vector for the transfer of diseases.\n\n3. **Climate Change**: Alterations in climate patterns can shift wildlife populations and their habitats, bringing them into closer contact with human communities. Warmer temperatures may also expand the range of vectors like mosquitoes that transmit diseases.\n\n4. **Biodiversity Loss**: Loss of biodiversity can disrupt ecosystems, leading to increased contact between humans and wildlife, and potentially allowing more infectious agents to transfer to humans.\n\nThese factors collectively contribute to the increasing frequency and intensity of spillover events, highlighting the interconnectedness of human health, wildlife health, and ecosystem health."
    },
    "644108b157b1c7a315000053":
    {
        "question": "What are the most commonly used pain scales for the measurement of pain in ICU?",
        "llm_evidence": "In the Intensive Care Unit (ICU), reliable measurement of pain is crucial for effective treatment, and several pain scales have been validated for use in critically ill patients. The most commonly used pain scales include:\n\n1. **Numeric Rating Scale (NRS)**: Patients rate their pain on a scale from 0 (no pain) to 10 (worst possible pain). This scale is simple and effective for patients who are alert and able to communicate their pain levels.\n\n2. **Visual Analog Scale (VAS)**: This involves a line, typically 10 cm long, where patients mark their pain intensity. It provides a visual representation of pain and is useful for patients who may have difficulty with numeric ratings.\n\n3. **Faces Pain Scale-Revised (FPS-R)**: Often used for non-verbal patients or those with communication difficulties, this scale uses facial expressions to indicate levels of pain, allowing caregivers to assess discomfort more intuitively.\n\n4. **Behavioral Pain Scale (BPS)**: Designed for patients who are sedated or unable to communicate verbally, BPS assesses pain through specific behaviors such as facial expressions, arm movements, and compliance with the ventilator.\n\n5. **Critical-Care Pain Observation Tool (CPOT)**: This scale scores patients across four categories (facial expressions, body movements, muscle tension, and compliance with ventilation), making it suitable for assessing pain in non-communicative patients, particularly those under sedation or with cognitive impairments.\n\nThese scales are essential for accurately identifying and managing pain in ICU patients, promoting comfort, and enhancing recovery outcomes."
    },
    "65d373e21930410b13000049":
    {
        "question": "What medication were tested in the PEMMELA trial?",
        "llm_evidence": "The PEMMELA trial investigated the efficacy of pembrolizumab, an immune checkpoint inhibitor, in patients with advanced melanoma. This trial specifically focused on the combination of pembrolizumab and talimogene laherparepvec (T-VEC), an oncolytic virus therapy. The aim was to evaluate the safety and effectiveness of this combination therapy in enhancing the immune response against melanoma, compared to pembrolizumab alone. Key insights from the trial indicated that combining these therapies could potentially improve response rates and overall survival in patients with unresectable melanoma."
    },
    "65f77328c4010b4d78000023":
    {
        "question": "What is the pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa?",
        "llm_evidence": "The pathophysiological mechanism by which microbiota contribute to the development of malignant lesions in the colonic mucosa involves several key processes:\n\n1. **Dysbiosis**: An imbalance in the gut microbiota, known as dysbiosis, can lead to an overgrowth of pathogenic bacteria and a reduction in beneficial ones. This imbalance is associated with chronic inflammation.\n\n2. **Inflammation**: Certain microbiota, such as those that produce lipopolysaccharides (LPS), can provoke an inflammatory response, resulting in the production of pro-inflammatory cytokines. Chronic inflammation is a known risk factor for colorectal cancer, as it can lead to DNA damage and promote tumorigenesis.\n\n3. **Metabolite Production**: The gut microbiota produce various metabolites, including short-chain fatty acids (SCFAs) and potentially harmful substances like secondary bile acids. While SCFAs can be protective against cancer, an overabundance of secondary bile acids can promote tumor growth.\n\n4. **Carcinogenic Compounds**: Certain bacterial species can generate carcinogenic compounds, such as N-nitroso compounds, through metabolic processes. These compounds can directly damage the DNA of colonic epithelial cells, leading to mutations and malignant transformation.\n\n5. **Immune Modulation**: The microbiota can influence the host's immune system, either enhancing anti-tumor immunity or facilitating tumor progression through immune evasion. Altered immune responses can allow malignant lesions to develop and proliferate.\n\n6. **Epithelial Barrier Dysfunction**: Dysbiosis and resultant inflammation can lead to damage of the epithelial barrier, allowing microbial translocation and further immune stimulation, creating a cycle that promotes malignancy.\n\nTogether, these mechanisms illustrate how gut microbiota play a critical role in the complex interplay between inflammation, immune response, and tissue damage, ultimately contributing to the development of malignant lesions in the colonic mucosa."
    },
    "65ef83acdffffb9b6b000002":
    {
        "question": "is carotenodermia caused by an excess of lycopene in the diet?",
        "llm_evidence": "Carotenodermia is a condition characterized by a yellowing of the skin, primarily caused by an excess intake of carotenoids, particularly beta-carotene, found in fruits and vegetables such as carrots and sweet potatoes. While lycopene, a carotenoid present in tomatoes and other red fruits, is known for its antioxidant properties, it is not typically associated with causing carotenodermia. The condition arises when there is an overload of certain carotenoids that the body cannot adequately metabolize. Lycopene does not convert to vitamin A in the body like beta-carotene does and has different metabolic pathways. Evidence suggests that while high doses of beta-carotene can lead to carotenodermia, lycopene does not have the same effect, making carotenodermia unrelated to excess lycopene intake."
    },
    "65f85231c4010b4d7800004d":
    {
        "question": "Which are the two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis)?",
        "llm_evidence": "The two main active ingredients of standard PrEP (Pre-Exposure Prophylaxis) are tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). TDF is a nucleotide reverse transcriptase inhibitor that helps prevent the replication of HIV by interfering with its ability to utilize the host's cellular mechanisms. FTC, also a reverse transcriptase inhibitor, works synergistically with TDF to enhance protection against the virus. Together, these medications have been shown to significantly reduce the risk of HIV infection in high-risk populations when taken consistently as prescribed."
    },
    "6451007857b1c7a315000093":
    {
        "question": "What is the cause of Leigh syndrome?",
        "llm_evidence": "Leigh syndrome, a severe neurodegenerative disorder, is primarily caused by genetic mutations affecting mitochondrial function. These mutations can occur in nuclear DNA or mitochondrial DNA, leading to defects in oxidative phosphorylation, which is critical for energy production in cells. Key insights include:\n\n1. **Genetic Mutations**: Over 75 genes have been associated with Leigh syndrome, including those involved in ATP synthesis and mitochondrial metabolism, such as the SURF1, LRPPRC, and NDUFS1 genes.\n\n2. **Mitochondrial Dysfunction**: The disorder is characterized by impaired mitochondrial function, resulting in insufficient energy supply to the brain and other vital organs, leading to neurodevelopmental delays, seizures, and other profound neurological symptoms.\n\n3. **Inheritance Patterns**: Leigh syndrome can exhibit various inheritance patterns, including autosomal recessive, autosomal dominant, and maternal inheritance, reflecting its heterogeneous genetic basis.\n\n4. **Clinical Presentation**: Symptoms typically emerge in infancy or early childhood and may include developmental regression, hypotonia, ataxia, and lactic acidosis, indicating a broader metabolic dysfunction.\n\nUnderstanding these factors is essential for diagnosing and managing Leigh syndrome, as well as for potential therapeutic interventions targeting mitochondrial health."
    },
    "65d129621930410b1300002e":
    {
        "question": "What is Primary Diffuse Meningeal Melanomatosis?",
        "llm_evidence": "Primary Diffuse Meningeal Melanomatosis (PDMM) is a rare and aggressive form of melanoma that specifically affects the meninges, which are the protective layers surrounding the brain and spinal cord. Characterized by the widespread dissemination of malignant melanocytic cells in the leptomeninges, PDMM can arise without prior cutaneous melanoma or may occur as a progression from existing melanoma. \n\nKey insights include:\n\n1. **Clinical Presentation**: Patients may exhibit symptoms such as headaches, neurological deficits, seizures, and signs of increased intracranial pressure due to the meningeal involvement.\n\n2. **Diagnosis**: Diagnosis is typically achieved through imaging studies like MRI, which can reveal characteristic meningeal enhancement, and by cerebrospinal fluid (CSF) analysis, which often shows the presence of malignant cells.\n\n3. **Prognosis and Treatment**: The prognosis for PDMM is generally poor, with a median survival of less than one year. Treatment options are limited and typically involve palliative care, as traditional therapies like surgery and radiation may not be effective due to the diffuse nature of the disease. Systemic therapies for metastatic melanoma may provide some benefits in selected cases.\n\n4. **Understanding the Disease**: PDMM underscores the importance of recognizing atypical presentations of melanoma and the potential for metastatic spread to the central nervous system, highlighting the need for vigilance in monitoring patients with a history of melanoma.\n\nOverall, PDMM represents a challenging subtype of melanoma, requiring a multidisciplinary approach for management due to its complex nature and aggressive behavior."
    },
    "65f77236c4010b4d7800001f":
    {
        "question": "Do black race patients have worse survival in colorectal cancer?",
        "llm_evidence": "Research has consistently shown that Black patients with colorectal cancer tend to experience worse survival outcomes compared to their white counterparts. Key insights include:\n\n1. **Disparities in Diagnosis**: Black patients are often diagnosed at later stages of colorectal cancer, which is associated with poorer survival rates. This delay can be attributed to factors such as limited access to healthcare, lack of screening, and differences in symptom recognition.\n\n2. **Biologic Differences**: Studies suggest that there may be biological factors that influence tumor behavior and treatment response in Black patients. These may include genetic variations that affect disease progression and response to therapies.\n\n3. **Socioeconomic Factors**: Disparities related to socioeconomic status, including income, education, and insurance coverage, impact access to timely and effective treatment options, which can affect survival rates.\n\n4. **Healthcare Access**: Black patients may face systemic barriers to healthcare, such as discrimination, which can limit their access to quality treatment and follow-up care, exacerbating survival disparities.\n\n5. **Lifestyle and Comorbidities**: Higher rates of comorbid conditions such as diabetes and hypertension in Black populations can negatively affect overall health, reducing the ability to tolerate potentially life-saving treatments.\n\nThese factors collectively contribute to the observed disparities in survival outcomes for Black patients with colorectal cancer, highlighting the need for targeted interventions to address these inequalities."
    },
    "65f1dadac4010b4d78000007":
    {
        "question": "Can Antioxidant curcumin kill tumor cells?",
        "llm_evidence": "Curcumin, the active compound found in the spice turmeric, has been extensively studied for its potential anti-cancer properties. Research indicates that curcumin can induce apoptosis (programmed cell death) in various tumor cell lines, including breast, colorectal, and prostate cancers. It achieves this through multiple mechanisms: curcumin inhibits key signaling pathways involved in cell proliferation and survival, such as NF-ÎºB and STAT3, and it modulates the expression of various genes related to cancer progression.\n\nAdditionally, studies have shown that curcumin can enhance the effectiveness of other chemotherapeutic agents and reduce drug resistance in tumor cells. Animal studies and preliminary clinical trials have reported promising results regarding curcumin's ability to target cancer cells selectively while sparing normal cells. However, despite these findings, the bioavailability of curcumin is relatively low, which raises challenges for its therapeutic application.\n\nOverall, the evidence suggests that curcumin has the potential to kill tumor cells and could be a valuable adjunct in cancer therapy, although further research is needed to optimize its delivery and efficacy."
    },
    "65f85f77c4010b4d78000053":
    {
        "question": "Should we treat all patients with glaucoma?",
        "llm_evidence": "Glaucoma is a progressive eye disease that can lead to irreversible vision loss, making timely treatment essential for preserving eyesight. However, not all patients exhibit the same severity or risk for visual impairment. Key insights in considering whether to treat all patients with glaucoma include:\n\n1. **Types of Glaucoma**: Different types exist, such as open-angle and angle-closure glaucoma, with varying treatment protocols. Open-angle glaucoma typically requires lifelong management, while angle-closure may necessitate more immediate intervention.\n\n2. **Staging and Risk Assessment**: Treatment decisions often depend on the stage of glaucoma. Patients with early-stage glaucoma may be monitored closely, while those with moderate to advanced disease usually need immediate treatment to prevent vision loss.\n\n3. **Individualized Treatment Plans**: Factors such as age, overall health, and patient preferences should guide treatment plans. Not all patients may require aggressive intervention; some may benefit from observation.\n\n4. **Potential Side Effects**: Treatments, including medications and surgeries, carry risks and potential side effects that need evaluation against the benefits for each individual patient.\n\n5. **Preventive Care and Monitoring**: Some patients, particularly those at high risk, may need proactive management even if they are asymptomatic, highlighting the importance of regular eye exams and personalized care rather than a blanket treatment approach.\n\nIn summary, while glaucoma is a serious condition that often requires treatment, the decision should be individualized based on the type of glaucoma, disease severity, patient characteristics, and the potential risks associated with treatments."
    },
    "65cfab681930410b13000012":
    {
        "question": "What is the mechanism of action of Pegozafermin?",
        "llm_evidence": "Pegozafermin is a novel peptide therapeutic that functions as a glucagon-like peptide-1 (GLP-1) receptor agonist. Its mechanism of action primarily involves two key pathways: enhancing insulin secretion and decreasing glucagon release from the pancreas. By binding to GLP-1 receptors, Pegozafermin stimulates insulin production in response to meals, leading to improved glycemic control. Additionally, it slows gastric emptying, which contributes to increased satiety and reduced appetite, promoting weight loss. The drug also has potential effects on reducing liver fat content, making it a promising option for conditions associated with metabolic syndrome, such as non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. Thus, Pegozafermin operates through a multifaceted approach, affecting glucose metabolism and energy homeostasis."
    },
    "65f70b9cc4010b4d7800001c":
    {
        "question": "What is the indication for Alirocumab?",
        "llm_evidence": "Alirocumab is a monoclonal antibody that targets PCSK9 (proprotein convertase subtilisin/kexin type 9) and is primarily indicated for the treatment of hyperlipidemia, specifically to lower low-density lipoprotein cholesterol (LDL-C) levels in adults with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH). It is used as an adjunct to diet and maximally tolerated statin therapy when additional LDL-C reduction is necessary. Clinical trials have demonstrated that Alirocumab significantly reduces LDL-C levels and can lead to a reduction in cardiovascular events in high-risk patients."
    },
    "65f86a90c4010b4d78000057":
    {
        "question": "Is there an approved vaccine against Helicobacter pylori?",
        "llm_evidence": "As of October 2023, there is no approved vaccine specifically against Helicobacter pylori (H. pylori), a bacterium implicated in peptic ulcer disease and gastric cancer. While various research groups have been exploring vaccine candidates targeting H. pylori, including both short peptide and whole-cell approaches, none have successfully completed the entire clinical trial process for regulatory approval. \n\nKey insights include:\n\n1. **Research and Development**: Several vaccine candidates have shown promise in preclinical models, but challenges persist in human trials, such as achieving sustainable immunity and the bacterium's ability to evade the immune response.\n\n2. **Current Treatment Options**: The standard treatment for H. pylori infection involves a combination of antibiotics and acid-reducing medications. Due to increasing antibiotic resistance, the need for a vaccine has been emphasized in the medical community.\n\n3. **Global Burden**: H. pylori infections are prevalent worldwide, making the development of an effective vaccine a public health priority. However, the complexity of the immune response prompted by H. pylori complicates vaccine development efforts.\n\nIn conclusion, while progress continues in understanding and addressing H. pylori infections, as of now, there is no licensed vaccine available."
    },
    "65cec1fb1930410b13000005":
    {
        "question": "What disease can be treated with Tebentafusp?",
        "llm_evidence": "Tebentafusp is an innovative immunotherapy specifically indicated for the treatment of metastatic uveal melanoma, a rare and aggressive form of eye cancer. It functions as a bispecific T cell engager (BiTE) that targets both the melanoma cells and the patient's T cells, enhancing the immune response against the cancer. Clinical trials have demonstrated that Tebentafusp significantly improves survival outcomes in patients with this disease, marking it as the first approved therapy for metastatic uveal melanoma, which historically had limited treatment options."
    },
    "65f856a1c4010b4d7800004e":
    {
        "question": "When was Havana Syndrome first recognized?",
        "llm_evidence": "Havana Syndrome was first recognized in late 2016 when U.S. and Canadian diplomats stationed in Havana, Cuba, began reporting unusual symptoms such as dizziness, headaches, fatigue, and cognitive difficulties. The phenomenon drew significant attention after multiple individuals experienced similar ailments, raising concerns about a possible sonic attack or exposure to a harmful agent. The U.S. government initiated investigations into the matter, officially defining the syndrome in 2017 as they sought to understand its causes and potential implications for national security and diplomatic personnel."
    },
    "65f86f03c4010b4d7800005b":
    {
        "question": "Is Marburg virus a member of the family of the Ebola virus (Filoviridae)?",
        "llm_evidence": "Yes, the Marburg virus is indeed a member of the Filoviridae family, the same family that includes the Ebola virus. Both viruses are classified as filoviruses, which are characterized by their filamentous structure. The Filoviridae family is known for causing severe hemorrhagic fevers in humans and non-human primates. Key insights include the following: \n\n1. **Genetic Similarity**: Both Marburg and Ebola viruses share significant genetic similarities, which allows them to be categorized under the same family.\n2. **Pathogenicity**: Viruses from the Filoviridae family, including Marburg and Ebola, are known for their high mortality rates and ability to cause outbreaks of disease.\n3. **Transmission and Symptoms**: Both viruses have similar modes of transmission, primarily through direct contact with bodily fluids, and cause similar clinical symptoms such as fever, bleeding, and organ failure.\n\nIn summary, the Marburg virus and Ebola virus are both part of the Filoviridae family, sharing characteristics that underline their classification and the severe impact they can have on health."
    },
    "65d140e71930410b1300003f":
    {
        "question": "What medications were tested in the COSMIC-313 trial?",
        "llm_evidence": "The COSMIC-313 trial investigated the combination of cabozantinib, a tyrosine kinase inhibitor, with immune checkpoint inhibitors. Specifically, it evaluated cabozantinib in conjunction with nivolumab (an anti-PD-1 antibody) and ipilimumab (an anti-CTLA-4 antibody) in patients with previously untreated advanced renal cell carcinoma (RCC). The trial aimed to assess the safety, tolerability, and efficacy of this triplet therapy compared to standard treatment options. Key insights indicated that the addition of cabozantinib may enhance anti-tumor activity by targeting multiple pathways, potentially leading to improved patient outcomes in RCC management."
    },
    "65f492bbc4010b4d78000011":
    {
        "question": "Explain the action of Domperidone.",
        "llm_evidence": "Domperidone is a medication primarily used as an antiemetic and gastroprokinetic agent. It works by blocking dopamine D2 receptors in the gastrointestinal tract and the chemoreceptor trigger zone of the central nervous system. By antagonizing these receptors, Domperidone enhances gastric emptying, decreases nausea and vomiting, and increases the movement of the stomach and intestines. Unlike metoclopramide, Domperidone has a limited ability to cross the blood-brain barrier, which minimizes central nervous system side effects such as sedation. Its effects are particularly beneficial in managing conditions like gastroparesis, nausea related to chemotherapy, and symptoms of Parkinson's disease when related to gastric motility. Overall, Domperidoneâs mechanism of action revolves around promoting gut motility and alleviating symptoms of nausea with reduced central nervous system impact."
    },
    "65f86ba3c4010b4d78000059":
    {
        "question": "Which age group should never be tested for HIV infection?",
        "llm_evidence": "There are certain age groups where routine HIV testing is not recommended, particularly in very young children. The Centers for Disease Control and Prevention (CDC) and various health organizations emphasize that infants and young children (particularly those under the age of 2) should never undergo testing unless they are considered at high risk for HIV exposure, such as those born to HIV-positive mothers. This is due to the potential for false positives and the complexities involved in interpreting test results in this age group. Additionally, testing is not typically warranted for individuals in the general population who are not at risk, as it can lead to unnecessary anxiety and medical procedures. Instead, the focus is on prevention, education, and targeted screening for high-risk populations."
    },
    "65d12ae11930410b13000030":
    {
        "question": "Can fingolimod be used during pregnancy?",
        "llm_evidence": "Fingolimod is an immunomodulatory medication primarily used to treat multiple sclerosis. However, its use during pregnancy is highly controversial and generally not recommended. Key insights include:\n\n1. **Teratogenic Risks**: Studies have indicated that fingolimod may pose risks of teratogenic effects, with animal studies showing adverse outcomes such as fetal malformations and negative impacts on embryonic development.\n\n2. **Pharmacokinetics**: Fingolimod is known to cross the placenta, which raises concerns about potential exposure to the developing fetus. The drug has a long half-life, which can prolong fetal exposure even after discontinuation.\n\n3. **Pregnancy Registry Findings**: The European Pregnancy Registry has recorded various adverse outcomes associated with fingolimod use during pregnancy, including complications and malformations.\n\n4. **Recommendations**: Most health guidelines, including those from the FDA and the manufacturer, advise against the use of fingolimod during pregnancy and suggest that women of childbearing potential should use effective contraception while on the medication.\n\n5. **Alternative Treatments**: Healthcare providers often recommend alternative therapies that have a more established safety profile during pregnancy for women with multiple sclerosis.\n\nIn summary, due to potential risks of teratogenicity and the implications for fetal development, fingolimod is generally not recommended for use during pregnancy."
    },
    "65f38059c4010b4d7800000e":
    {
        "question": "What does capnography measure?",
        "llm_evidence": "Capnography measures the concentration of carbon dioxide (CO2) in exhaled air, providing real-time feedback on a patientâs ventilatory status. It quantifies the partial pressure of CO2 and displays it as a waveform on a monitor. Key insights include:\n\n1. **End-tidal CO2 (ETCO2)**: This is the maximum concentration of CO2 at the end of expiration, reflecting the effectiveness of ventilation and the metabolic state of the patient.\n   \n2. **Monitoring Trends**: Capnography is crucial in various clinical settings, including anesthesia, emergency medicine, and critical care, for detecting hypoventilation, hyperventilation, and changes in pulmonary function.\n\n3. **Application in Intubation**: It serves as a valuable tool during intubation to confirm tube placement in the trachea, as proper ventilation results in a characteristic capnographic waveform.\n\n4. **Clinical Relevance**: Abnormal capnography readings can indicate respiratory failure, circulation issues, or metabolic disturbances, thus guiding appropriate medical interventions. \n\nOverall, capnography is an essential non-invasive monitoring tool for assessing ventilation and ensuring patient safety in clinical environments."
    },
    "65f8611dc4010b4d78000055":
    {
        "question": "Should men be immunized against Human Papilloma Virus?",
        "llm_evidence": "Immunizing men against Human Papilloma Virus (HPV) is supported by several key insights:\n\n1. **Prevalence of HPV**: HPV is one of the most common sexually transmitted infections, affecting both men and women. Approximately 50% of sexually active individuals will contract HPV at some point in their lives. \n\n2. **Health Risks for Men**: While HPV is often associated with cervical cancer in women, it can also lead to other serious health issues in men, including genital warts and several types of cancers (such as anal, penile, and oropharyngeal cancers).\n\n3. **Transmission**: Men can transmit HPV to their female partners, contributing to the risk of cervical cancer in women. By vaccinating men, the overall prevalence of the virus can be reduced, thereby protecting both men and women.\n\n4. **Vaccination Efficacy**: The HPV vaccine has been shown to be effective in reducing the incidence of HPV-related diseases in both genders. Vaccination during adolescence is particularly effective because it is most successful when given before the onset of sexual activity.\n\n5. **Public Health Strategy**: Widespread immunization of young men, in combination with the vaccination of women, aligns with public health strategies aimed at reducing the overall burden of HPV-related diseases and achieving herd immunity.\n\nIn conclusion, immunizing men against HPV is a critical aspect of comprehensive HPV prevention efforts that promotes health equity, protects against various cancers, and contributes to the reduction of HPV transmission within the community."
    },
    "65cfd68a1930410b13000021":
    {
        "question": "Is sectoral Heterochromia associated with Crohn's disease?",
        "llm_evidence": "Sectoral heterochromia, characterized by a difference in coloration in segments of the iris, is not widely recognized as a direct association with Crohn's disease in scientific literature. However, there are anecdotal reports and case studies suggesting possible connections between various autoimmune conditions, including Crohn's disease, and phenotypic variations in ocular features. \n\nKey insights include:\n\n1. **Autoimmune Link**: Crohn's disease is an autoimmune disorder that can lead to extraintestinal manifestations affecting multiple systems, including the eyes. Certain ocular manifestations associated with autoimmune diseases can include changes to pigmentation, though the specific association with sectoral heterochromia is not firmly established.\n\n2. **Genetic Factors**: Some studies indicate that genetic predisposition may influence both autoimmune conditions and iris pigmentation, suggesting a potential, albeit indirect, relationship. \n\n3. **Clinical Observations**: There are isolated clinical observations where patients with Crohn's disease have exhibited unique eye features, including alterations in iris pigmentation. These observations could warrant further investigation but do not indicate a causal relationship.\n\nIn conclusion, while there is no conclusive evidence directly linking sectoral heterochromia to Crohn's disease, the potential for a connection via autoimmune mechanisms and genetic factors merits additional research to clarify possible associations."
    },
    "65f377d5c4010b4d78000009":
    {
        "question": "List the most effective treatment methods for Madelung disease.",
        "llm_evidence": "Madelung disease, also known as Launois-Bensaude syndrome, is characterized by the formation of lipomas, particularly around the neck and shoulders. The most effective treatment methods include:\n\n1. **Surgical Excision**: This is the primary treatment method for patients with significant symptoms or aesthetic concerns. Complete removal of the lipomas can relieve pressure on surrounding structures and improve appearance.\n\n2. **Liposuction**: In cases where the lipomas are large and fibrous, liposuction may be employed to reduce the volume of fat. This technique can be less invasive and allows for quicker recovery compared to traditional surgery.\n\n3. **Weight Management**: Though not a direct treatment, maintaining a healthy weight may help manage symptoms and prevent further lipoma development, as the condition can be exacerbated by obesity.\n\n4. **Medication**: While there is no specific drug treatment for Madelung disease, some anecdotal evidence suggests that medications targeting lipid metabolism could be beneficial for managing fat deposits, although further research is needed to confirm this.\n\nOverall, surgical options remain the most widely accepted and effective methods for treating Madelung disease, particularly for symptomatic relief and cosmetic improvement."
    },
    "65f847c5c4010b4d78000046":
    {
        "question": "What are common side effects of the progesterone-only pill (POP)?",
        "llm_evidence": "The progesterone-only pill (POP), also known as the mini-pill, is a type of hormonal contraceptive that primarily uses the hormone progestin. Common side effects associated with the use of POP include irregular menstrual bleeding, such as spotting or changes in the frequency and duration of periods. Other potential side effects may include headaches, breast tenderness, mood swings, and acne. Some users may also experience gastrointestinal issues like nausea. It is important to note that while side effects can occur, many women tolerate POP well, and some may have no side effects at all. Additionally, because POP does not contain estrogen, it is often recommended for women who cannot take estrogen-containing contraceptives, such as those who smoke or are over 35 years old."
    },
    "65d128f81930410b1300002d":
    {
        "question": "What is the mechanism of action of Peresolimab?",
        "llm_evidence": "Peresolimab is a monoclonal antibody that functions as an immune checkpoint inhibitor, specifically targeting the programmed cell death protein 1 (PD-1) receptor. By binding to PD-1, Peresolimab blocks its interaction with PD-L1 and PD-L2 ligands, thereby enhancing T-cell activation and proliferation. This mechanism counteracts the tumor-induced immune suppression, allowing the immune system to recognize and attack cancer cells more effectively. Additionally, Peresolimab has shown promise in treating various malignancies by reinvigorating exhausted T cells in the tumor microenvironment, contributing to improved anti-tumor responses."
    },
    "65f1d021c4010b4d78000004":
    {
        "question": "Explain the difference between eosinophilic esophagitis and reflux-induced esophagitis.",
        "llm_evidence": "Eosinophilic esophagitis (EoE) and reflux-induced esophagitis are both conditions affecting the esophagus, but they have distinct etiologies and characteristics. EoE is an allergic inflammatory condition characterized by an elevated number of eosinophils (a type of white blood cell) in the esophagus. It is often related to food allergies or environmental allergens and can lead to symptoms such as dysphagia (difficulty swallowing), food impaction, and chest pain. The diagnosis is typically confirmed through endoscopy and biopsy showing eosinophilic infiltration.\n\nIn contrast, reflux-induced esophagitis is a result of gastroesophageal reflux disease (GERD), where stomach acid irritates the esophageal lining. This condition is primarily caused by a malfunctioning lower esophageal sphincter that allows acidic stomach contents to back up into the esophagus. Symptoms include heartburn, regurgitation, and sometimes chest pain. Diagnosis is often made based on symptoms and may be supported by endoscopy revealing inflammation and erosions in the esophagus.\n\nKey insights that differentiate the two include: \n1. **Pathophysiology**: EoE involves an allergic reaction with eosinophilic infiltration, while reflux-induced esophagitis is due to acid damage.\n2. **Symptoms**: EoE typically presents with food-related symptoms, whereas reflux-induced esophagitis primarily manifests as heartburn.\n3. **Diagnosis**: EoE is diagnosed via biopsy showing eosinophils, whereas reflux-induced esophagitis is diagnosed through symptom evaluation and visual inspection of esophageal damage. \n\nUnderstanding these differences is crucial for appropriate diagnosis and treatment."
    },
    "65f84aa5c4010b4d78000047":
    {
        "question": "What are the most common symptoms of fibroids?",
        "llm_evidence": "Fibroids, also known as uterine leiomyomas, are noncancerous growths in the uterus that can cause a variety of symptoms. The most common symptoms include:\n\n1. **Heavy Menstrual Bleeding:** Many women experience prolonged and heavy menstrual periods (menorrhagia), which can lead to anemia.\n2. **Pelvic Pain or Pressure:** This can manifest as a feeling of fullness or pressure in the pelvic area, particularly if the fibroids are large.\n3. **Frequent Urination:** Location of fibroids can put pressure on the bladder, leading to increased urgency and frequency of urination.\n4. **Pain During Intercourse:** Fibroids can cause discomfort or pain during sexual intercourse due to their position in the uterus.\n5. **Lower Back Pain:** Some women report persistent lower back discomfort, which can be related to the size and location of fibroids.\n6. **Bloating or Swelling:** Fibroids can lead to a visible swelling in the abdomen, making women feel bloated.\n\nThese symptoms can vary in intensity and may not all be present in every woman with fibroids. Seeking medical advice is important for proper diagnosis and management."
    },
    "65cfa22b1930410b1300000c":
    {
        "question": "What is the target of Selpercatinib?",
        "llm_evidence": "Selpercatinib is a targeted therapy specifically designed to inhibit the RET (rearranged during transfection) kinase. It is primarily used in the treatment of patients with RET-altered cancers, including non-small cell lung cancer (NSCLC) and certain types of thyroid cancer. Selpercatinib works by blocking the activity of the RET protein, which is involved in cell signaling pathways that promote tumor growth and survival. This selective inhibition leads to reduced proliferation of RET-dependent tumors and has shown significant efficacy in patients with RET fusions and mutations. Clinical trials have demonstrated its effectiveness and favorable safety profile, establishing it as a vital therapy for those with RET-driven malignancies."
    },
    "65f5a319c4010b4d78000016":
    {
        "question": "What is IL-35?",
        "llm_evidence": "IL-35, or Interleukin-35, is a member of the interleukin-12 cytokine family, primarily produced by regulatory T cells (Tregs) and regulatory B cells. It plays a crucial role in immune regulation and suppression of inflammatory responses. IL-35 functions by inhibiting the activation and proliferation of other immune cells, particularly effector T cells and dendritic cells, thereby promoting immune tolerance. This cytokine is significant in maintaining homeostasis within the immune system, contributing to the prevention of autoimmune diseases and excessive inflammatory responses. Recent studies have also suggested a potential role for IL-35 in cancer progression by subverting anti-tumor immunity. Overall, IL-35 is essential for controlling immune responses and maintaining the balance between tolerance and immunity."
    },
    "65f84535c4010b4d78000044":
    {
        "question": "What are the transmission mechanisms of the human Ebola infection?",
        "llm_evidence": "Ebola virus transmission occurs through multiple mechanisms primarily involving direct contact with infected bodily fluids. Key insights include:\n\n1. **Human-to-Human Transmission**: The virus spreads via direct contact with blood, saliva, sweat, vomit, feces, or other bodily fluids of infected individuals. This is particularly prominent during the symptomatic phase of the illness.\n\n2. **Healthcare Settings**: Healthcare workers are at heightened risk due to exposure during treatment of infected individuals, especially in areas lacking adequate infection control measures. Transmission can occur through needle-stick injuries or contact with contaminated medical equipment.\n\n3. **Environmental Contamination**: The virus can survive outside the human body for several hours to days on surfaces, leading to transmission if individuals come into contact with contaminated objects.\n\n4. **Sexual Transmission**: The Ebola virus can persist in certain body fluids like semen for an extended period post-recovery. There have been documented cases of transmission through sexual contact with male survivors.\n\n5. **Contact with Infected Animals**: Initial outbreaks often link to zoonotic transmission from wildlife (e.g., bats, primates), suggesting that handling or consuming infected animals can introduce the virus to humans.\n\nUnderstanding these mechanisms is crucial for implementing effective control measures to prevent Ebola outbreaks."
    },
    "65ce88be1930410b13000002":
    {
        "question": "What is the mechanisms of action of Sotorasib?",
        "llm_evidence": "Sotorasib is a targeted therapy specifically designed to inhibit the mutated form of the KRAS protein, which is commonly associated with various cancers, particularly non-small cell lung cancer (NSCLC). Its mechanism of action primarily involves the following key insights:\n\n1. **KRAS G12C Inhibition**: Sotorasib selectively targets the KRAS G12C mutation, a specific alteration that occurs in the KRAS gene. This mutation leads to continuous activation of downstream signaling pathways that promote cell proliferation and survival.\n\n2. **Binding Mechanism**: The drug binds covalently to the cysteine residue of the KRAS G12C mutant protein, locking it in an inactive state. This disrupts its ability to transmit growth signals through the RAS-MAPK and PI3K-AKT pathways, ultimately leading to reduced tumor growth and survival.\n\n3. **Antitumor Activity**: Clinical studies have shown that Sotorasib effectively reduces tumor size and improves progression-free survival in patients with KRAS G12C-mutated tumors. Its efficacy is particularly notable in NSCLC but is also being explored in other malignancies with the same mutation.\n\n4. **Personalized Medicine**: Sotorasib represents a significant advancement in personalized cancer therapy, providing an option for patients whose tumors harbor the KRAS G12C mutation, emphasizing the move toward targeted and individualized treatment strategies in oncology.\n\nIn summary, Sotorasib functions by specifically inhibiting the KRAS G12C mutation, thereby interfering with critical signaling pathways that drive the growth of certain cancers."
    },
    "65f039fdc4010b4d78000002":
    {
        "question": "What is the vector for coxiella burnetii transmission?",
        "llm_evidence": "Coxiella burnetii, the causative agent of Q fever, is primarily transmitted to humans through inhalation of contaminated aerosols, particularly from environments contaminated with the bacteria, such as barnyards or livestock facilities. The main vectors for transmission are domesticated animals, especially cattle, sheep, and goats, which shed the bacteria in their feces, urine, milk, and birthing products. The bacteria can survive in the environment for long periods, making it possible for people to become infected even without direct contact with infected animals. Additionally, tick bites are considered a potential, though less common, route of transmission. Understanding these transmission dynamics is crucial for controlling outbreaks and ensuring public health safety."
    },
    "65f82fe1c4010b4d7800003f":
    {
        "question": "Methotrexate is an antifolate medication.",
        "llm_evidence": "Methotrexate is an antifolate medication that works by inhibiting the enzyme dihydrofolate reductase (DHFR), which is crucial for the synthesis of folate. By blocking this enzyme, methotrexate reduces the production of tetrahydrofolate, a form of folate necessary for DNA synthesis and repair. This mechanism makes methotrexate effective in treating various conditions, including certain cancers, autoimmune diseases like rheumatoid arthritis, and ectopic pregnancies. Its antifolate properties also lead to its use in combination therapies where suppression of rapidly dividing cells is necessary. Additionally, methotrexate's ability to deplete folate can result in side effects, necessitating supplementation with folic acid in some cases to mitigate toxicity."
    },
    "65d131451930410b13000034":
    {
        "question": "Is GC1118 effective for glioblastoma?",
        "llm_evidence": "GC1118, a monoclonal antibody targeting the human epidermal growth factor receptor (HER) pathway, has shown promise in clinical settings for treating glioblastoma multiforme (GBM). Glioblastoma is notoriously resistant to conventional therapies, leading to a need for innovative approaches. Recent studies indicate that GC1118 may enhance anti-tumor immunity and inhibit tumor growth by blocking the HER signaling pathway. In preclinical trials, GC1118 demonstrated the ability to impede cell proliferation and promote apoptosis in glioblastoma cell lines. Additionally, early-phase clinical trials have reported some tumor shrinkage and improved patient outcomes when GC1118 was used in combination with other therapies, suggesting its potential as an effective treatment option for glioblastoma. However, more extensive clinical trials are needed to establish its overall efficacy and safety profile in larger patient populations."
    },
    "65f70d71c4010b4d7800001e":
    {
        "question": "Is COACH syndrome a rare autosomal recessive genetic disease characterized by liver fibrosis and related to portal hypertension.",
        "llm_evidence": "COACH syndrome, which stands for cholangitis, obliterative bronchitis, autoimmune hepatitis, cryptogenic cirrhosis, and hepatopulmonary syndrome, is indeed a rare autosomal recessive genetic disease. It is characterized by a combination of liver dysfunction, including fibrosis and cirrhosis, often leading to portal hypertension. The disease is primarily linked to mutations in the EPHX1 gene, which affects hepatic functions and can lead to the accumulation of bile acids in the liver, resulting in liver injury and the associated complications. Portal hypertension occurs as a consequence of increased portal venous pressure due to liver fibrosis and cirrhosis. Hence, COACH syndrome is characterized by significant liver-related symptoms and a rare genetic inheritance pattern."
    },
    "65f86f62c4010b4d7800005c":
    {
        "question": "Which symptoms could indicate depression in young children?",
        "llm_evidence": "Depression in young children can manifest through a variety of symptoms that may differ from those seen in older individuals. Key insights include:\n\n1. **Mood Changes**: Persistent sadness, irritability, or mood swings are common. Children may seem more withdrawn or show a lack of interest in activities they once enjoyed.\n\n2. **Behavioral Symptoms**: Increased anger, tantrums, or disruptive behavior can be indicative of underlying depression. Some children may also exhibit regressive behaviors, such as bedwetting or thumb sucking.\n\n3. **Changes in Sleep Patterns**: Insomnia, nightmares, or excessive sleeping can signal depression. Difficulty waking up or reluctance to go to school may also be present.\n\n4. **Appetite and Weight Changes**: Eating disturbances, such as a significant increase or decrease in appetite, can reflect emotional distress.\n\n5. **Cognitive Impairments**: Trouble concentrating, making decisions, or remembering things may be signs of depression. Young children might express these through difficulties in school or play.\n\n6. **Physical Complaints**: Unexplained physical symptoms like stomachaches or headaches are common among depressed children and may be used to express emotional pain.\n\nRecognizing these signs early is crucial for intervention and support, as young children may lack the verbal skills to articulate their feelings directly."
    },
    "65d136bc1930410b1300003c":
    {
        "question": "What are active ingredients of Paxlovid?",
        "llm_evidence": "Paxlovid is an oral antiviral medication used to treat COVID-19. It consists of two active ingredients: nirmatrelvir and ritonavir. \n\n1. **Nirmatrelvir**: This compound is a protease inhibitor that specifically targets the SARS-CoV-2 virus, inhibiting its replication by blocking the activity of the main protease necessary for viral protein processing. \n\n2. **Ritonavir**: While originally developed as an HIV protease inhibitor, ritonavir is included in Paxlovid primarily to boost the effectiveness of nirmatrelvir. It inhibits the metabolic breakdown of nirmatrelvir, allowing higher concentrations of the antiviral to remain in the body for an extended period.\n\nTogether, these ingredients work synergistically to reduce the viral load in patients with COVID-19, ultimately improving clinical outcomes and reducing the risk of severe illness."
    },
    "65f37997c4010b4d7800000b":
    {
        "question": "What is an Albatross plot used for?",
        "llm_evidence": "An Albatross plot, also known as a 'funnel plot,' is primarily used in the field of meta-analysis and health research to visualize the relationship between study size (or precision) and effect size. It helps identify potential publication bias by displaying the results of individual studies against their sample sizes or standard errors. In an Albatross plot, the y-axis represents the effect size (e.g., odds ratios or mean differences), while the x-axis represents the inverse of the standard error. The expected distribution under the null hypothesis forms a funnel shape; asymmetry in the distribution can indicate the presence of biases, such as unpublished negative results. Overall, Albatross plots serve as a tool for researchers to assess the robustness of their findings and the validity of their conclusions in systematic reviews."
    },
    "65f85df3c4010b4d78000051":
    {
        "question": "What should you do if you find an individual that you suspect has overdosed?",
        "llm_evidence": "If you suspect an individual has overdosed, follow these key steps:\n\n1. **Assess the Situation:** Ensure the environment is safe for you to approach the individual and check for responsivenessâshake their shoulders and shout to wake them up.\n\n2. **Call for Help:** If the person is unresponsive or you suspect a serious overdose, call emergency services immediately. Provide them with as much information as possible about the situation and the substances involved, if known.\n\n3. **Check Vital Signs:** Monitor the personâs breathing and pulse. If they are not breathing or breathing abnormally (e.g., slow or gasping), be prepared to administer CPR.\n\n4. **Administer Naloxone:** If available and you suspect an opioid overdose, you can use Naloxone (Narcan). This medication can rapidly reverse the effects of opioid overdose and can be administered by nasal spray or injection.\n\n5. **Position the Individual:** If the person is unconscious but breathing, place them in the recovery position (on their side) to prevent choking in case they vomit.\n\n6. **Stay With Them:** Remain with the individual until help arrives, providing reassurance and monitoring their condition. Do not leave them alone, as their status could deteriorate.\n\n7. **Do Not Administer Substances:** Avoid giving the individual food, water, or any stimulants, as these can complicate the situation.\n\nActing quickly and following these steps can significantly improve the chances of recovery for someone experiencing an overdose."
    },
    "65cebf371930410b13000004":
    {
        "question": "What is the mechanism of action of sparsentan?",
        "llm_evidence": "Sparsentan is a dual endothelin receptor antagonist and angiotensin II receptor blocker, designed primarily for the treatment of kidney diseases such as focal segmental glomerulosclerosis (FSGS) and IgA nephropathy. Its mechanism of action involves selectively inhibiting both the endothelin type A (ETA) and type B (ETB) receptors and blocking the angiotensin II type 1 (AT1) receptor. \n\nBy antagonizing the ETA receptor, sparsentan reduces vasoconstriction and mitigates the profibrotic effects of endothelin-1, a peptide involved in renal and cardiovascular diseases. Inhibition of the AT1 receptor decreases the effects of angiotensin II, leading to reduced blood pressure and decreased fluid retention. This dual-action not only helps lower blood pressure but also offers renal protective effects, ultimately aiming to slow the progression of kidney damage and improve renal function. Clinical studies have indicated that this combination approach may lead to better outcomes in terms of proteinuria reduction and kidney preservation compared to traditional therapies."
    },
    "65f70915c4010b4d7800001a":
    {
        "question": "Please summarize MuSK Antibody positive Myasthenia Gravis.",
        "llm_evidence": "MuSK (Muscle-Specific Kinase) antibody positive Myasthenia Gravis (MG) is an autoimmune disorder characterized by the presence of antibodies that target the MuSK protein, critical for neuromuscular junction formation and maintenance. This condition predominantly affects women and typically presents in younger adults, though it can occur at any age. Symptoms include pronounced muscle weakness, which can fluctuate and is exacerbated by activity, often affecting muscles controlling eye movements, facial expression, and swallowing.\n\nKey insights include:\n\n1. **Pathophysiology**: In MuSK antibody positive MG, the immune system mistakenly attacks MuSK, disrupting acetylcholine receptor clustering at the neuromuscular junction, leading to impaired communication between nerves and muscles.\n\n2. **Clinical Features**: Patients commonly experience ocular symptoms (e.g., ptosis, diplopia), generalized muscle weakness, and bulbar symptoms (e.g., dysphagia). Unlike acetylcholine receptor antibody positive MG, patients with MuSK antibodies may have less severe ocular impairment but more significant bulbar and limb weakness.\n\n3. **Diagnosis**: Diagnosis often involves serological testing for MuSK antibodies, as well as electromyography (EMG) tests that show a decremental response in muscle stimulation.\n\n4. **Management**: Treatment options include symptomatic management with acetylcholinesterase inhibitors, immunosuppressive therapies (e.g., corticosteroids, azathioprine), and in some cases, plasma exchange or intravenous immunoglobulin (IVIG) during myasthenic crises.\n\n5. **Prognosis**: While MuSK antibody positive MG can be more treatment-resistant compared to the more common AChR antibody positive variant, many patients respond well to immunotherapy, leading to improved muscle strength and quality of life.\n\nIn summary, MuSK antibody positive Myasthenia Gravis is a distinct subtype of MG with specific pathogenic mechanisms, demographic tendencies, and treatment approaches that differentiate it from other forms of the disease."
    },
    "65f8418fc4010b4d78000041":
    {
        "question": "Is it advisable to bring the fever down when it is supposedly meant to assist in the fight of disease?",
        "llm_evidence": "Fever is a natural response of the body to infection, acting as a defensive mechanism that can help inhibit the growth of pathogens and enhance immune function. Research indicates that moderate fevers can optimize the activity of immune cells, such as T-lymphocytes and macrophages, which are crucial in battling infections. Lowering a fever, especially with medications like acetaminophen or ibuprofen, can provide comfort but may also interfere with the body's ability to fight the underlying illness. \n\nHowever, there are instances where reducing a high fever (typically above 102Â°F or 39Â°C) is necessary to prevent complications, especially in vulnerable populations like young children or individuals with certain medical conditions. Therefore, the general recommendation is to monitor the fever and treat it if it becomes excessively high or leads to discomfort, rather than automatically lowering it for every mild or moderate fever. \n\nIn summary, while managing fever can be important for comfort, it is advisable to allow some fevers to run their course when they are moderate, as they can be beneficial in the immune response to infection."
    },
    "65cfd13f1930410b1300001d":
    {
        "question": "Can syphilis cause proctitis?",
        "llm_evidence": "Yes, syphilis can cause proctitis, particularly in individuals who engage in anal intercourse. Proctitis is defined as inflammation of the rectum, and it can be caused by sexually transmitted infections (STIs), including syphilis. In cases of secondary syphilis, patients may exhibit mucous membrane lesions that can affect the rectal area, leading to symptoms such as pain, discharge, and bleeding. Furthermore, syphilis can coexist with other STIs that are known to cause proctitis, such as gonorrhea and chlamydia, increasing the likelihood of rectal inflammation in infected individuals. The recognition and treatment of syphilis are crucial in preventing complications such as proctitis and transmission to sexual partners."
    },
    "65f493cac4010b4d78000012":
    {
        "question": "What disorder is considered off label use for domperidone?",
        "llm_evidence": "Domperidone is primarily approved for the treatment of nausea and vomiting, but it is often used off-label for various other disorders, notably for the management of gastrointestinal motility disorders and for enhancing lactation in breastfeeding mothers. The use of domperidone to increase milk production is particularly common, as it acts as a dopamine antagonist that can increase levels of prolactin, a hormone crucial for milk production. Although this off-label use is not officially sanctioned by regulatory agencies, many healthcare providers may prescribe it for this purpose based on clinical experience and patient needs. Additionally, some may explore its potential benefits in treating symptoms associated with conditions like gastroesophageal reflux disease (GERD) or functional dyspepsia, where gastric emptying delays and nausea are present. However, it's important to note that the off-label use of domperidone is accompanied by safety considerations, as it can lead to cardiac side effects, particularly in patients with pre-existing heart conditions."
    },
    "65f8721ec4010b4d7800005d":
    {
        "question": "Which neurotransmitters are thought to play a role in obsessive compulsive disorder?",
        "llm_evidence": "Obsessive-Compulsive Disorder (OCD) is thought to involve several neurotransmitters, with the most prominent being serotonin, dopamine, and glutamate.\n\n1. **Serotonin**: Research suggests that serotonin dysregulation is a key factor in OCD. Many effective treatments, such as selective serotonin reuptake inhibitors (SSRIs), enhance serotonin levels, indicating its critical role in symptom management.\n\n2. **Dopamine**: Studies have shown that altered dopamine activity may contribute to the compulsions and repetitive behaviors characteristic of OCD. The role of dopamine in the brain's reward pathways can influence obsessive thoughts and compulsive actions.\n\n3. **Glutamate**: Emerging evidence indicates that glutamatergic dysfunction may also play a part in OCD. Glutamate is the primary excitatory neurotransmitter in the brain, and abnormalities in its signaling may impact the neural circuits involved in the disorder.\n\nOverall, the interaction between these neurotransmitters suggests a complex neurobiological underpinning of OCD, where imbalances can lead to the manifestation of obsessive thoughts and compulsive behaviors."
    },
    "65d126d21930410b1300002c":
    {
        "question": "Can denosumab cause jaw necrosis?",
        "llm_evidence": "Denosumab is a medication primarily used to treat osteoporosis and certain types of cancer-related bone conditions by inhibiting osteoclast formation and activity, thereby reducing bone resorption. However, it has been associated with the risk of osteonecrosis of the jaw (ONJ), a condition where the jawbone becomes exposed and begins to die due to a reduced blood supply. This risk is particularly elevated in patients undergoing dental procedures, those with existing dental issues, or those receiving high doses of denosumab for cancer treatment. Key insights indicating a link between denosumab and jaw necrosis include:\n\n1. **Clinical Studies**: Research has shown a statistically significant incidence of ONJ in patients receiving denosumab, especially when compared to the general population.\n  \n2. **Guidelines and Warnings**: The prescribing information for denosumab explicitly warns about the potential risk of ONJ and advises patients to maintain good oral hygiene and undergo dental evaluations before starting treatment.\n\n3. **Mechanism of Action**: The inhibition of osteoclast activity by denosumab may disrupt the normal bone remodeling process, potentially increasing the risk of bone necrosis under certain conditions.\n\n4. **Patient Factors**: Risk factors such as concurrent use of other medications (like bisphosphonates), the patient's dental health, and duration of therapy play significant roles in the likelihood of developing ONJ.\n\nThese points collectively highlight that while denosumab can be an effective treatment for certain conditions, it carries a risk of jaw necrosis, which clinicians and patients need to carefully monitor."
    },
    "65f37871c4010b4d7800000a":
    {
        "question": "What is DEXTR",
        "llm_evidence": "DEXTR (Decentralized Exchange Token Registry) is a platform that facilitates the creation and management of decentralized exchanges (DEXs) and their associated tokens. Its primary goal is to promote transparency and interoperability among DEXs by providing a standardized registry for token information. Key insights about DEXTR include:\n\n1. **Decentralization**: DEXTR adheres to the core principles of decentralization, allowing users to trade tokens directly without intermediaries, thus enhancing security and privacy.\n\n2. **Token Standardization**: It establishes a uniform protocol for tokens, enabling seamless integration and transferability across various DEX platforms, which fosters a more interconnected ecosystem.\n\n3. **Governance**: DEXTR may incorporate decentralized governance mechanisms, allowing token holders to participate in decision-making processes regarding platform developments and upgrades.\n\n4. **Liquidity and Accessibility**: By supporting multiple DEXs, DEXTR enhances liquidity accessibility for users, enabling a wider array of trading opportunities and potentially lower transaction costs.\n\n5. **Security Features**: DEXTR often emphasizes robust security protocols, reducing vulnerabilities commonly associated with centralized exchanges, such as hacking and fraud.\n\nOverall, DEXTR aims to empower users in the cryptocurrency space by providing a reliable and user-friendly environment for engaging in decentralized trading activities."
    },
    "65f85ec7c4010b4d78000052":
    {
        "question": "What is the most common surgical treatment for hydrocephalus?",
        "llm_evidence": "The most common surgical treatment for hydrocephalus is the placement of a ventriculoperitoneal (VP) shunt. This procedure involves inserting a flexible tube that drains excess cerebrospinal fluid (CSF) from the ventricles of the brain into the abdominal cavity, where the fluid can be absorbed. Key insights supporting this approach include its effectiveness in reducing intracranial pressure, the relatively low complication rates associated with the procedure, and its long-established use for both pediatric and adult patients. Alternative treatments, such as endoscopic third ventriculostomy (ETV), are available but are typically reserved for specific cases, making VP shunt placement the most prevalent surgical intervention for managing hydrocephalus."
    },
    "65d126471930410b1300002b":
    {
        "question": "Is Upadacitinib effective for Crohnâs Disease?",
        "llm_evidence": "Upadacitinib, an oral JAK inhibitor, has shown promising efficacy in treating moderate to severe Crohnâs Disease (CD) based on clinical trials. In pivotal studies such as the U-EXCEL and U-START trials, patients receiving Upadacitinib demonstrated significant improvement in clinical remission rates and response compared to placebo groups. The maintenance of remission was also observed, indicating sustained effectiveness over time. Additionally, Upadacitinib was found to improve quality of life and reduce disease activity in Crohnâs Disease patients. Safety profiles indicated manageable side effects, further supporting its use as a viable treatment option in clinical practice. Overall, these findings suggest that Upadacitinib is effective for managing Crohnâs Disease."
    },
    "65f0369bc4010b4d78000001":
    {
        "question": "Is melatonin beneficial in the treatment of in cerebral ischemia-reperfusion injury:",
        "llm_evidence": "Melatonin is a potent antioxidant that has been shown to have neuroprotective effects in various models of cerebral ischemia-reperfusion injury. Key insights supporting its benefits include:\n\n1. **Antioxidant Properties**: Melatonin scavenges free radicals and enhances mitochondrial function, which helps reduce oxidative stress associated with reperfusion injury.\n\n2. **Anti-inflammatory Effects**: It modulates inflammatory responses by downregulating pro-inflammatory cytokines and upregulating anti-inflammatory molecules, thus protecting neural tissues during ischemia-reperfusion.\n\n3. **Circadian Rhythm Regulation**: Melatonin helps stabilize circadian rhythms, which can improve overall brain function and resilience in response to ischemic events.\n\n4. **Neuronal Survival**: Studies demonstrate that melatonin administration post-injury promotes neuronal survival, reduces apoptosis, and improves functional recovery in animal models of stroke.\n\n5. **Clinical Implications**: Emerging clinical trials suggest that melatonin supplementation may enhance outcomes in stroke patients by mitigating ischemic damage and improving recovery trajectories.\n\nOverall, the accumulating evidence indicates that melatonin is beneficial in the context of cerebral ischemia-reperfusion injury, making it a potential therapeutic agent in stroke management."
    },
    "65f84b5ec4010b4d78000048":
    {
        "question": "Are Hemoglobin-Based Oxygen Carriers approved for human use?",
        "llm_evidence": "Hemoglobin-Based Oxygen Carriers (HBOCs) are synthetic or modified hemoglobin products that aim to serve as blood substitutes by carrying oxygen in the bloodstream. While there has been significant research and development around HBOCs, as of October 2023, no HBOC has received widespread regulatory approval for general human use. Some HBOCs, like Hemopure (bovine-derived) and Oxyglobin (canine use), have seen limited approvals, primarily in specific veterinary contexts or for niche applications, but human application remains controversial. Key challenges include adverse effects such as increased blood pressure and oxygen toxicity, leading to scrutiny from health regulators like the FDA and EMA. Ongoing clinical trials continue to assess their safety and efficacy, indicating the potential for future approval, but as of now, they are not widely approved for human use."
    },
    "65cfa37c1930410b1300000d":
    {
        "question": "Gantenerumab was developed for treatment of which disease?",
        "llm_evidence": "Gantenerumab is primarily developed for the treatment of Alzheimer's disease. It is a human monoclonal antibody that targets amyloid beta, a protein that forms plaques in the brains of Alzheimer's patients. Clinical studies have focused on evaluating its effectiveness in reducing amyloid plaque burden and improving cognitive function in individuals with mild to moderate Alzheimer's disease. The drug aims to modify the disease's progression rather than just alleviating symptoms, making it a part of ongoing research in neurodegenerative disease interventions."
    },
    "65f70a55c4010b4d7800001b":
    {
        "question": "Please list the congenital fibrinogen disorders.",
        "llm_evidence": "Congenital fibrinogen disorders are rare hereditary conditions characterized by deficiencies or dysfunctions of fibrinogen, a critical protein in the blood coagulation process. The key types of congenital fibrinogen disorders include:\n\n1. **Congenital Fibrinogen Deficiency ( afibrinogenemia)**: This is a complete absence of fibrinogen, leading to severe bleeding tendencies. Patients often present with excessive bleeding after trauma or surgery.\n\n2. **Hypofibrinogenemia**: This condition involves a reduced level of fibrinogen in the blood, which can cause mild to moderate bleeding symptoms. It may be asymptomatic in some cases.\n\n3. **Dysfibrinogenemia**: In this disorder, normal levels of fibrinogen are present, but the protein is structurally abnormal, leading to impaired clot formation. Symptoms can vary widely, with some patients experiencing bleeding while others may have a tendency for thrombosis.\n\n4. **Afibrinogenemia**: A complete lack of fibrinogen, this condition often results in significant bleeding complications and requires treatment with fibrinogen concentrate or cryoprecipitate.\n\nThese disorders may have varying clinical presentations and inherited patterns, primarily following an autosomal recessive or dominant inheritance. Diagnosis typically involves coagulation studies that assess fibrinogen levels and functionality. Management may require factor replacement therapy or supportive care during bleeding episodes."
    },
    "65f82218c4010b4d7800003e":
    {
        "question": "What are the current indications for thalidomide?",
        "llm_evidence": "Thalidomide is currently indicated for several conditions primarily related to its immunomodulatory and anti-inflammatory properties. Key insights include:\n\n1. **Multiple Myeloma**: Thalidomide is used in combination with other therapies for the treatment of newly diagnosed multiple myeloma, particularly in patients not eligible for stem cell transplantation.\n\n2. **Erythema Nodosum Leprosum (ENL)**: It is effective in treating leprosy-related conditions, specifically erythema nodosum leprosum, which is a painful skin condition that can occur in leprosy patients.\n\n3. **HIV-Induced Conditions**: Thalidomide may be used off-label for conditions like HIV-associated wasting syndrome, where it helps in weight gain and improving nutritional status.\n\n4. **Autoimmune Disorders**: There is a growing interest in the use of thalidomide for treating certain autoimmune conditions, such as BehÃ§et's disease, due to its immunosuppressive effects.\n\n5. **Cancer Therapies**: Research continues into its role in the treatment of other malignancies beyond multiple myeloma, exploring its potential for various hematologic and solid tumors.\n\n6. **Safety and Regulatory Status**: Due to its teratogenic effects, thalidomide is tightly regulated, and its use is associated with strict risk management programs to prevent exposure during pregnancy.\n\nOverall, the use of thalidomide has evolved substantially since the 1960s, shifting from its infamous history of causing birth defects to becoming a critical therapeutic agent in specific clinical settings."
    },
    "65d1357c1930410b13000039":
    {
        "question": "What is the administration route of zavegepant?",
        "llm_evidence": "Zavegepant is administered as a nasal spray. This route allows for rapid absorption and onset of action, making it effective for acute treatment of migraine. Formulated as a selective CGRP receptor antagonist, zavegepant offers a non-invasive alternative to traditional oral medications, providing patients with an effective option for managing migraine symptoms quickly."
    },
    "65f59db8c4010b4d78000014":
    {
        "question": "Brunner's gland hamartoma (BGH) is often asymptomatic and so how is it usually diagnosed?",
        "llm_evidence": "Brunner's gland hamartoma (BGH) is typically diagnosed incidentally during imaging studies or endoscopic procedures conducted for other reasons, such as gastrointestinal complaints or routine examinations. Key insights include:\n\n1. **Imaging Techniques**: BGH can be identified through abdominal ultrasound, CT scans, or MRI, which may reveal a pancreaticoduodenal mass. These imaging modalities are sensitive in detecting abnormalities in the duodenum.\n\n2. **Endoscopy**: During upper gastrointestinal endoscopy (EGD), the hamartoma may be discovered when inspecting the duodenum, often appearing as a submucosal lesion. Biopsy may be performed, although BGH is usually benign and may not require further intervention.\n\n3. **Asymptomatic Nature**: Many individuals with BGH do not exhibit symptoms, leading to a diagnosis that is often made incidentally rather than through targeted investigation. In symptomatic cases that do arise, symptoms might include abdominal pain or gastrointestinal bleeding, prompting further examination.\n\n4. **Histological Confirmation**: Diagnosis can be confirmed through histological analysis of tissue obtained during biopsies, which can reveal the characteristic features of Brunner's gland tissue proliferation.\n\nIn summary, Brunner's gland hamartoma is usually diagnosed incidentally through imaging studies or endoscopic evaluations, with histological confirmation providing definitive diagnosis in some cases."
    },
    "65f86e06c4010b4d7800005a":
    {
        "question": "Is peritoneal dialysis the best option for infants with kidney failure?",
        "llm_evidence": "Peritoneal dialysis (PD) is often considered a viable option for infants with kidney failure due to its advantages in minimizing the risk of complications associated with hemodialysis. Key insights include:\n\n1. **Gentle Approach**: PD utilizes the peritoneum as a membrane for dialysis, providing a gentler method of fluid and waste removal, which can be less traumatic for infants compared to the more invasive hemodialysis procedures.\n\n2. **Stability and Flexibility**: PD generally allows for greater stability in an infantâs overall condition and can be performed at home, enabling better quality of life and reduced hospital visits.\n\n3. **Lower Complication Rates**: Studies have indicated that PD has lower rates of certain complications, such as infections and cardiovascular issues, when compared to hemodialysis in pediatric patients.\n\n4. **Nutritional Benefits**: PD is less likely to interfere with nutrition, which is critical for growth and development in infants, as it avoids the significant fluid shifts associated with hemodialysis.\n\n5. **Customized Treatment Plans**: PD can be tailored to meet the specific needs of infants, accommodating their size and individual medical conditions more effectively than other dialysis methods.\n\nIn summary, while there are several dialysis options available for infants with kidney failure, peritoneal dialysis is often favored due to its gentler approach, better compatibility with growth and nutrition, and lower complication rates. However, individual circumstances and medical advice should always guide the final choice of treatment."
    },
    "65ce88b71930410b13000001":
    {
        "question": "Is Lecanemab approved for Alzheimerâs Disease?",
        "llm_evidence": "Lecanemab is a monoclonal antibody designed to target amyloid beta plaques in the brain, which are associated with Alzheimerâs disease. In January 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Lecanemab under the brand name Leqembi. This approval was based on data from clinical trials demonstrating that Lecanemab can reduce amyloid plaques and slightly slow cognitive decline in early Alzheimerâs patients. The primary trial showed a statistically significant reduction in the decline of cognitive function compared to placebo. However, ongoing monitoring and further studies are required to fully understand its long-term effectiveness and safety profile. With this approval, Lecanemab represents a significant advancement in the treatment options available for Alzheimerâs disease."
    },
    "65f5a3efc4010b4d78000017":
    {
        "question": "Can Ultrasonography be used to detect tumors in dogs and cats?",
        "llm_evidence": "Yes, ultrasonography can be used to detect tumors in dogs and cats. This non-invasive imaging technique utilizes high-frequency sound waves to create real-time images of internal structures, allowing veterinarians to visualize abnormal growths within organs and tissues. Key insights include:\n\n1. **Soft Tissue Imaging**: Ultrasonography excels at imaging soft tissues, making it particularly effective for identifying tumors in organs such as the liver, kidneys, spleen, and bladder.\n\n2. **Guidance for Biopsy**: Ultrasound can serve as a guiding tool for aspirating cells from suspected tumors for cytological analysis, enhancing diagnostic accuracy.\n\n3. **Early Detection**: Regular ultrasonography can aid in the early detection of tumors, potentially leading to better treatment outcomes as tumors can be identified before they progress significantly.\n\n4. **Complementary Tool**: While not definitive on its own, ultrasound is often used alongside other diagnostic modalities, such as radiography (X-rays) and CT scans, to provide a comprehensive evaluation of suspected tumors.\n\nOverall, ultrasonography is a valuable tool in the veterinary diagnostic process for identifying and assessing tumors in dogs and cats."
    },
    "65f82058c4010b4d7800003d":
    {
        "question": "What is the first line treatment for severe Plasmodium falciparum malaria?",
        "llm_evidence": "The first-line treatment for severe Plasmodium falciparum malaria is intravenous (IV) artesunate. According to the World Health Organization (WHO), artesunate is preferred over other treatments due to its rapid action and efficacy in reducing mortality. In situations where IV artesunate is unavailable, other options may include IV quinine. Early treatment is critical to prevent complications, and a transition to oral antimalarial medication, such as artemether-lumefantrine, is often recommended once the patient stabilizes. Ensuring the management of complications, such as respiratory distress or renal failure, is also crucial in the treatment protocol for severe cases."
    }
}